SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-303296
Filing Date
2022-12-13
Accepted
2022-12-13 09:06:07
Documents
16
Period of Report
2022-12-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d411279d8k.htm   iXBRL 8-K 36294
2 EX-99.1 d411279dex991.htm EX-99.1 36401
3 EX-99.2 d411279dex992.htm EX-99.2 3580
7 GRAPHIC g411279g1213022233966.jpg GRAPHIC 32234
8 GRAPHIC g411279imgex2.jpg GRAPHIC 6513
  Complete submission text file 0001193125-22-303296.txt   267087

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA gmtx-20221211.xsd EX-101.SCH 2872
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE gmtx-20221211_lab.xml EX-101.LAB 17979
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gmtx-20221211_pre.xml EX-101.PRE 11273
10 EXTRACTED XBRL INSTANCE DOCUMENT d411279d8k_htm.xml XML 3405
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Filer) CIK: 0001816736 (see all company filings)

IRS No.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39438 | Film No.: 221458652
SIC: 2834 Pharmaceutical Preparations